Cholesgen to enter into a drug discovery collaboration and licensing option agreement in hypercholesterolemia with AstraZeneca

High levels of cholesterol are a major risk factor for atherosclerotic cardiovascular disease (ASCVD). ASCVD remains a leading cause of death worldwide, despite advances in preventive interventions. High levels of cholesterol are a major risk factor for atherosclerotic cardiovascular disease (ASCVD). ASCVD remains a leading cause of death worldwide, despite advances in preventive interventions. "This is an important collaboration for AstraZeneca, led by deep scientific expertise and a shared...

High levels of cholesterol are a major risk factor for atherosclerotic cardiovascular disease (ASCVD). ASCVD remains a leading cause of death worldwide, despite advances in preventive interventions.

"This is an important collaboration for AstraZeneca, led by deep scientific expertise and a shared ambition to address the key drivers that contribute to hypercholesterolemia and related metabolic diseases. We look forward to working together to accelerate target discovery and preclinical research in this area of high unmet need." said Mene Pangalos, EVP, BioPharmaceuticals R&D, AstraZeneca.

"As a young Biotech with deep understanding of target biology and a focused pipeline, Cholesgen is thrilled to start this strategic collaboration with AstraZeneca and hope to accelerate the delivery of innovative medicines for patients with hypercholesterolemia or related metabolic diseases," said Dr. Bao-Liang Song, Chair of SAB Cholesgen.

About "Cholesgen"

Cholesgen (Shanghai) Co. Ltd. is a biotech pioneering in the biomedical research, innovative target identification and first-in-class drug discovery in the field of cholesterol-related diseases, such as hyperlipidemia, obesity, atherosclerosis, and nonalcoholic steatohepatitis.  

View original content:https://www.prnewswire.co.uk/news-releases/cholesgen-to-enter-into-a-drug-discovery-collaboration-and-licensing-option-agreement-in-hypercholesterolemia-with-astrazeneca-301852803.html